MRI-guided treat-to-target treatment for patients with rheumatoid arthritis is no better than conventional treat-to-target strategies, researchers reported in JAMA in February. However, in a new commentary posted this month in JAMA, researchers raise some interesting points experts may want to reconsider.
Patient access to biologic therapies is an issue throughout the European Union where the authors of a review article zero in on “why.” Access issues, they find, have a lot in common with access issues here in the U.S.
Belgian researchers sought to determine which patients are appropriate candidates for tapering biologics. In this article, we summarize their findings.
One caveat: because several risk estimates reached higher confidence intervals, a clinically meaningful risk cannot be completely ruled out.
Here: 6 key beliefs patients hold about DMARDs that drive their reluctance to continue therapy.
Here’s a brief look at medications for rheumatologic disorders that were approved or granted a new indication in 2018.
This novel interleukin-23 inhibitor targets psoriatic inflammation.
In late-breaking clinical trials, 3 novel biologic drugs show promise for the treatment of moderate to severe plaque psoriasis.
However, the degree to which biosimilars will drive down the cost of biologic therapy remains to be seen.
The aim of this study: to determine which patients need biologic therapy after starting methotrexate.